Evotec SE (XSWX:EVT) Other Current Receivables: CHF62.6 Mil (As of Mar. 2026)


XSWX:EVT Evotec SE XSWX:EVT
68 GF Score
Price CHF4.50
GF Value CHF6.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Other Current Receivables?

Evotec SE XSWX:EVT +4.02% 68 Other Current Receivables is CHF62.6 Mil as of Mar. 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 68/100 and a GF Value™ of CHF6.99 (Possible Value Trap). The stock has 5 warning signs investors should review.

Evotec SE's Other Current Receivables for the quarter that ended in Mar. 2026 was CHF62.6 Mil.

Evotec SE's quarterly Other Current Receivables declined from Sep. 2025 (CHF83.05 Mil) to Dec. 2025 (CHF72.36 Mil) but then stayed the same from Dec. 2025 (CHF72.36 Mil) to Mar. 2026 (CHF62.61 Mil).

Evotec SE's annual Other Current Receivables declined from Dec. 2023 (CHF116.47 Mil) to Dec. 2024 (CHF95.29 Mil) and declined from Dec. 2024 (CHF95.29 Mil) to Dec. 2025 (CHF72.36 Mil).

Evotec SE Other Current Receivables Related Terms

Evotec SE Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Evotec SE's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Other Current Receivables Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.49 102.61 116.47 95.29 72.36

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.67 78.24 83.05 72.36 62.61
XSWX:EVT
68GF Score
Evotec SE XSWX:EVT
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of CHF62.6 Mil mean?
Evotec SE (XSWX:EVT) has a Other Current Receivables of CHF62.6 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Evotec SE and its competitors.
Is Evotec SE's Other Current Receivables too high?
Evotec SE's current Other Current Receivables is CHF62.6 Mil. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Other Current Receivables compare to ZTS and UTHR?
Evotec SE's Other Current Receivables of CHF62.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Evotec SE and its competitors. Evotec SE's current Other Current Receivables is CHF62.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Other Current Receivables is CHF62.6 Mil. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Other Current Receivables is CHF62.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (XSWX:EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for XSWX:EVT:

  • Other Current Receivables: CHF62.6 Mil
  • GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score

Get the complete analysis for XSWX:EVT

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF4.50
Price
CHF6.99
GF Value